Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
McKesson
AstraZeneca
Colorcon
Boehringer Ingelheim

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,070,998

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,070,998
Title:Adeno-associated virus materials and methods
Abstract: The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.
Inventor(s): Johnson, Jr.; Philip R. (Wynnewood, PA)
Assignee: Children\'s Hospital, Inc. (Columbus, OH)
Application Number:11/063,903
Patent Claims:1. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus, wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes, and wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.

2. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus, wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes, wherein the recombinant adeno-associated virus genome comprises adeno-associated virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to promoter and polyadenylation sequences, and wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.

3. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus, wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes, wherein the recombinant adeno-associated virus genome comprises adeno-associated virus inverted terminal repeats flanking DNA sequences encoding a polypeptide selected from the group consisting of tyrosine hydroxylase, aromatic amino acid decarboxylase, nerve growth factor, brain derived neurotrophic factor, NT-3, NT-4/5, glial derived neurotrophic factor and fibroblast growth factor, the DNA sequences being operably linked to promoter and polyadenylation sequences, and wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.

4. A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus, wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes, wherein the recombinant adeno-associated virus genome comprises the cytomegalovirus (CMV) immediate early promoter, the rabbit .beta.-globin intron, the human immunodeficiency virus rev/envelope sequences and the rabbit .beta.-globin polyadenylation signal, and wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.

Details for Patent 7,070,998

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Children\'s Hospital, Inc. (Columbus, OH) 2014-06-06 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Children\'s Hospital, Inc. (Columbus, OH) 2014-06-06 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Children\'s Hospital, Inc. (Columbus, OH) 2014-06-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKinsey
Express Scripts
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.